Clinical Trial Update: A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated the safety and pharmacokinetics of a PARP inhibitor in combination with dacarbazine for melanoma, and the study is reported as complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• PARP inhibitor

Snippet

Sponsor: AstraZeneca | Conditions: Melanoma Neoplasms | Phase 1 | Status: COMPLETED